Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
16alpha-hydroxydehydroepiandrosterone 3-sulfate + H2O
16alpha-hydroxydehydroepiandrosterone + sulfate
-
-
-
-
?
17beta-estradiol sulfate + H2O
17beta-estradiol + sulfate
3beta-hydroxyandrost-5-en-17-one 3-sulfate + H2O
3beta-hydroxyandrost-5-en-17-one + sulfate
4-methylumbelliferyl sulfate + H2O
4-methylumbelliferol + sulfate
-
-
-
-
?
4-methylumbelliferyl sulfate + H2O
4-methylumbelliferone + sulfate
4-methylumbelliferyl-6-O-sulfate + H2O
4-methylumbelliferone + sulfate
-
-
-
-
?
4-nitrophenyl sulfate + H2O
4-nitrophenol + sulfate
7-dehydroepiandrosterone sulfate + H2O
7-dehydroepiandrosterone + sulfate
-
-
-
-
?
androstenediol 3-sulfate + H2O
androstenediol + sulfate
-
-
-
-
?
androstenediol sulfate + H2O
androstenediol + sulfate
-
-
-
-
?
androstenediol-3-sulfate + H2O
androstenediol + sulfate
-
-
-
-
?
androsterone 3-sulfate + H2O
androsterone + sulfate
-
-
-
?
arylsulfates + H2O
? + sulfate
-
e.g. 3alpha sulfates of: 5alpha-androstane-17-one, 5beta-androstane-17-one, 3beta sulfates of: 5alpha-androstane-17-one, DELTA5-androstene 17-one, 5alpha-pregnane-20-one, DELTA5-pregnene-20-one
-
-
?
arzoxifene sulfate + H2O
arzoxifene + sulfate
-
product of sulfotransferase reaction on arzoxifene used in hormone replacement therapy
-
-
?
beta-estradiol-3-sulfate + H2O
estradiol + sulfate
-
-
-
-
?
boldenone 17-sulfate + H2O
boldenone + sulfate
-
-
-
?
cholesterol 3-sulfate + H2O
cholesterol + sulfate
cholesterol sulfate + H2O
cholesterol + sulfate
cortisone 21-sulfate + H2O
cortisone + sulfate
-
-
-
-
?
dehydroandrosterone 3-sulfate + H2O
dehydroandrosterone + sulfate
dehydroepiandrosterone 3-sulfate + H2O
dehydroepiandrosterone + sulfate
dehydroepiandrosterone sulfate + H2O
dehydroepiandrosterone + sulfate
dehydroisoandrosterone 3-sulfate + H2O
dehydroisoandrosterone + sulfate
-
-
-
-
?
epiandrosterone 3-sulfate + H2O
epiandrosterone + sulfate
epitestosterone 17-sulfate + H2O
epitestosterone + sulfate
-
-
-
?
estrone 3-sulfate + H2O
estrone + sulfate
estrone sulfate
estrone + sulfate
-
-
-
?
estrone sulfate + H2O
estrone + sulfate
etiocholanolone 3-sulfate + H2O
etiocholanolone + sulfate
-
-
-
?
methylumbelliferyl sulfate + H2O
methylumbelliferone + sulfate
-
-
-
-
?
p-acetylphenyl sulfate + H2O
p-acetylphenol + sulfate
-
-
-
-
?
p-nitrocatechol sulfate + H2O
nitrocatechol + sulfate
-
-
-
-
?
p-nitrophenyl-sulfate + H2O
p-nitrophenol + sulfate
phenolphthalein disulfate + H2O
phenolphthalein monosulfate + sulfate
-
-
-
-
?
pregnenolone 3-sulfate + H2O
pregnenolone + sulfate
pregnenolone sulfate + H2O
pregnenolone + sulfate
raloxifene sulfate + H2O
raloxifene + sulfate
-
product of sulfotransferase reaction on raloxifene used in hormone replacement therapy, the benzothiophene sulfate is substrate, the 4'-phenolic sulfate is no substrate for enzyme
-
-
?
steroid sulfate + H2O
steroid + sulfate
steroid sulfates + H2O
steroid + sulfate
testosterone 17-sulfate + H2O
testosterone + sulfate
-
-
-
?
testosterone 3-sulfate + H2O
testosterone + sulfate
additional information
?
-
17beta-estradiol sulfate + H2O
17beta-estradiol + sulfate
-
-
-
?
17beta-estradiol sulfate + H2O
17beta-estradiol + sulfate
-
-
-
-
?
17beta-estradiol sulfate + H2O
17beta-estradiol + sulfate
-
-
-
?
3beta-hydroxyandrost-5-en-17-one 3-sulfate + H2O
3beta-hydroxyandrost-5-en-17-one + sulfate
-
-
-
-
?
3beta-hydroxyandrost-5-en-17-one 3-sulfate + H2O
3beta-hydroxyandrost-5-en-17-one + sulfate
-
-
-
-
?
3beta-hydroxyandrost-5-en-17-one 3-sulfate + H2O
3beta-hydroxyandrost-5-en-17-one + sulfate
-
-
-
-
?
3beta-hydroxyandrost-5-en-17-one 3-sulfate + H2O
3beta-hydroxyandrost-5-en-17-one + sulfate
-
-
-
-
?
3beta-hydroxyandrost-5-en-17-one 3-sulfate + H2O
3beta-hydroxyandrost-5-en-17-one + sulfate
-
-
-
-
?
3beta-hydroxyandrost-5-en-17-one 3-sulfate + H2O
3beta-hydroxyandrost-5-en-17-one + sulfate
-
-
-
-
?
4-methylumbelliferyl sulfate + H2O
4-methylumbelliferone + sulfate
-
-
-
-
?
4-methylumbelliferyl sulfate + H2O
4-methylumbelliferone + sulfate
-
-
-
?
4-methylumbelliferyl sulfate + H2O
4-methylumbelliferone + sulfate
-
both s-form and f-form
-
-
?
4-nitrophenyl sulfate + H2O
4-nitrophenol + sulfate
Haliotis sp.
-
-
-
-
?
4-nitrophenyl sulfate + H2O
4-nitrophenol + sulfate
-
-
-
-
?
4-nitrophenyl sulfate + H2O
4-nitrophenol + sulfate
-
-
-
-
?
4-nitrophenyl sulfate + H2O
4-nitrophenol + sulfate
-
-
-
?
cholesterol 3-sulfate + H2O
cholesterol + sulfate
-
-
-
?
cholesterol 3-sulfate + H2O
cholesterol + sulfate
-
-
-
-
?
cholesterol 3-sulfate + H2O
cholesterol + sulfate
-
-
-
?
cholesterol 3-sulfate + H2O
cholesterol + sulfate
-
only s-form
-
-
?
cholesterol 3-sulfate + H2O
cholesterol + sulfate
-
-
-
-
?
cholesterol sulfate + H2O
cholesterol + sulfate
-
-
-
-
?
cholesterol sulfate + H2O
cholesterol + sulfate
-
cholesterol sulfate metabolism, steroid sulfohydrolase pathway
-
-
?
cholesterol sulfate + H2O
cholesterol + sulfate
-
highly specific for cholesterol sulfate
-
-
?
dehydroandrosterone 3-sulfate + H2O
dehydroandrosterone + sulfate
-
-
-
-
?
dehydroandrosterone 3-sulfate + H2O
dehydroandrosterone + sulfate
-
-
-
-
?
dehydroepiandrosterone 3-sulfate + H2O
dehydroepiandrosterone + sulfate
-
-
-
-
?
dehydroepiandrosterone 3-sulfate + H2O
dehydroepiandrosterone + sulfate
-
-
-
?
dehydroepiandrosterone 3-sulfate + H2O
dehydroepiandrosterone + sulfate
-
-
-
-
?
dehydroepiandrosterone 3-sulfate + H2O
dehydroepiandrosterone + sulfate
-
-
135598, 135603, 135604, 135611, 135614, 135616, 135617, 135624, 135628, 681648, 681650 -
-
?
dehydroepiandrosterone 3-sulfate + H2O
dehydroepiandrosterone + sulfate
-
-
-
?
dehydroepiandrosterone 3-sulfate + H2O
dehydroepiandrosterone + sulfate
-
-
-
-
?
dehydroepiandrosterone 3-sulfate + H2O
dehydroepiandrosterone + sulfate
-
only s-form
-
-
?
dehydroepiandrosterone 3-sulfate + H2O
dehydroepiandrosterone + sulfate
in adipose tissue, further concersion to bioactive androgens and estrogens
-
-
?
dehydroepiandrosterone 3-sulfate + H2O
dehydroepiandrosterone + sulfate
-
-
-
-
?
dehydroepiandrosterone 3-sulfate + H2O
dehydroepiandrosterone + sulfate
-
-
-
-
?
dehydroepiandrosterone 3-sulfate + H2O
dehydroepiandrosterone + sulfate
-
-
-
-
?
dehydroepiandrosterone 3-sulfate + H2O
dehydroepiandrosterone + sulfate
-
-
-
-
?
dehydroepiandrosterone 3-sulfate + H2O
dehydroepiandrosterone + sulfate
-
-
-
?
dehydroepiandrosterone 3-sulfate + H2O
dehydroepiandrosterone + sulfate
-
-
-
-
?
dehydroepiandrosterone sulfate + H2O
dehydroepiandrosterone + sulfate
-
-
-
-
?
dehydroepiandrosterone sulfate + H2O
dehydroepiandrosterone + sulfate
-
-
-
-
?
dehydroepiandrosterone sulfate + H2O
dehydroepiandrosterone + sulfate
-
conversion to androstenediol by 17beta-hydroxysteroid dehydrogenase type 1, androstenediol supports mammary tumor growth in rodents, or conversion to androstenedione, main substrate for aromatase in postmenopausal women
-
?
dehydroepiandrosterone sulfate + H2O
dehydroepiandrosterone + sulfate
-
-
subsequent conversion to andgrogen testosterone or androstenediol, androgens stimulate growth of prostate cancer cells
-
?
dehydroepiandrosterone sulfate + H2O
dehydroepiandrosterone + sulfate
-
-
subsequent conversion to androst-5-ene-3beta,17beta-diol (Adiol), an androgen with estrogenic properties, and thus a mitogen for the growth and development of hormome-dependent breast cancer
-
?
dehydroepiandrosterone sulfate + H2O
dehydroepiandrosterone + sulfate
-
subsequent conversion to androst-5-ene-3beta,17beta-diol, an androgen with estrogenic properties, stimulating breast cancer growth
-
?
dehydroepiandrosterone sulfate + H2O
dehydroepiandrosterone + sulfate
-
-
subsequent conversion to estradiol with 3beta-hydroxysteroid dehydrogenase, aromatase and 17beta-hydroxysteroid dehydrogenase
-
?
dehydroepiandrosterone sulfate + H2O
dehydroepiandrosterone + sulfate
-
-
subsequent conversion to testosterone
-
?
dehydroepiandrosterone sulfate + H2O
dehydroepiandrosterone + sulfate
-
androgen metabolism, dehydroepiandrosterone sulfate may play a part in the pathogenesis of androgenic alopecia
-
-
?
dehydroepiandrosterone sulfate + H2O
dehydroepiandrosterone + sulfate
-
hydrolyzes dehydroepiandrosterone sulfate to its active, unsulfated form
-
-
?
dehydroepiandrosterone sulfate + H2O
dehydroepiandrosterone + sulfate
-
oestrogen biosynthesis
-
-
?
dehydroepiandrosterone sulfate + H2O
dehydroepiandrosterone + sulfate
-
1.5% of the activity with cholesterol sulfate
-
-
?
dehydroepiandrosterone sulfate + H2O
dehydroepiandrosterone + sulfate
-
dehydroepiandrosterone is reduced to a diol by 17beta-HSD1, apart from estrone, the steroid sulfatase pathway is also responsible for the production of another steroid with estrogenic properties, namely androstenediol
-
-
?
dehydroepiandrosterone sulfate + H2O
dehydroepiandrosterone + sulfate
-
-
-
-
?
dehydroepiandrosterone sulfate + H2O
dehydroepiandrosterone + sulfate
-
-
subsequent conversion to testosterone or aromatisation to estrone
-
?
dehydroepiandrosterone sulfate + H2O
dehydroepiandrosterone + sulfate
-
-
-
-
?
dehydroepiandrosterone sulfate + H2O
dehydroepiandrosterone + sulfate
-
-
conversion to androstenediol by 17beta-hydroxysteroid dehydrogenase type 1, androstenediol supports mammary tumor growth in rodents, or conversion to androstenedione, main substrate for aromatase in postmenopausal women
-
?
dehydroepiandrosterone sulfate + H2O
dehydroepiandrosterone + sulfate
-
-
subsequent conversion to androst-5-ene-3beta,17beta-diol (Adiol), an androgen with estrogenic properties, and thus a mitogen for the growth and development of hormome-dependent breast cancer
-
?
epiandrosterone 3-sulfate + H2O
epiandrosterone + sulfate
-
-
-
-
?
epiandrosterone 3-sulfate + H2O
epiandrosterone + sulfate
-
-
-
?
estrone 3-sulfate + H2O
estrone + sulfate
-
-
-
?
estrone 3-sulfate + H2O
estrone + sulfate
-
-
-
-
?
estrone 3-sulfate + H2O
estrone + sulfate
-
-
-
?
estrone 3-sulfate + H2O
estrone + sulfate
-
hydrolyzes estrone 3-sulfate to its active, unsulfated form
-
-
?
estrone 3-sulfate + H2O
estrone + sulfate
-
-
-
?
estrone sulfate + H2O
estrone + sulfate
-
-
-
-
?
estrone sulfate + H2O
estrone + sulfate
-
-
135600, 135602, 135604, 135611, 135619, 135622, 135624, 645740, 645797, 656640, 656641, 656649, 656658, 681648, 691630, 702979, 703195, 705062, 705709, 714750, 714821, 714906, 716213, 716214 -
-
?
estrone sulfate + H2O
estrone + sulfate
-
conversion to estradiol by 17beta-hydroxysteroid dehydrogenase type 1
-
?
estrone sulfate + H2O
estrone + sulfate
-
-
estrogen estrone formed from androstenedione by cytochrome P450 enzyme aromatase, estrogen is a mitogen for growth and development of hormone-dependent breast cancer
-
?
estrone sulfate + H2O
estrone + sulfate
-
in breast cancer tissue 10 times more estrone originates from estrone sulfate than from androstenedione
-
?
estrone sulfate + H2O
estrone + sulfate
-
-
subsequent conversion to biologically active estrogen estradiol, increased activity and expression of STS in hormone-dependent cancer cells, estradiol prerequisite for Ishikawa cell tumorgenesis in ovariectomized mouse model, estrogens are suggested as growth stimulators in prostate cancer cells as well, subsequent conversion to estradiol
-
?
estrone sulfate + H2O
estrone + sulfate
-
-
subsequent conversion to estradiol
-
?
estrone sulfate + H2O
estrone + sulfate
-
-
subsequent conversion to estradiol with 17beta-hydroxysteroid dehydrogenase
-
?
estrone sulfate + H2O
estrone + sulfate
-
natural substrate
-
-
?
estrone sulfate + H2O
estrone + sulfate
-
only s-form
-
-
?
estrone sulfate + H2O
estrone + sulfate
-
STS converts the major circulating plasma estrogen estrone sulfate into the biologically active estrogene estrone, STS plays an important role in the in situ estrogen actions of various sex steroid-dependent tumors, peripheral STS plays a very important role in peripheral estrogen metabolism and actions in the human fetus
-
-
?
estrone sulfate + H2O
estrone + sulfate
-
STS plays an important role in the in situ estrogen actions of estrogen-dependent human tissues and various sex steroid-dependent tumors, STS may be associated with the degree of atherosclerotic changes in the female aorta, transformation of the biologically inactive form of plasma estrogen in its active form
-
-
?
estrone sulfate + H2O
estrone + sulfate
-
0.6% of the activity with cholesterol sulfate
-
-
?
estrone sulfate + H2O
estrone + sulfate
-
estrone is locally produced from circulating inactive estrone sulfate by steroid sulfatase
-
-
?
estrone sulfate + H2O
estrone + sulfate
-
-
-
-
?
estrone sulfate + H2O
estrone + sulfate
-
-
subsequent conversion to estradiol
-
?
estrone sulfate + H2O
estrone + sulfate
-
-
-
-
?
estrone sulfate + H2O
estrone + sulfate
-
-
-
-
?
estrone sulfate + H2O
estrone + sulfate
-
-
conversion to estradiol by 17beta-hydroxysteroid dehydrogenase type 1
-
?
estrone sulfate + H2O
estrone + sulfate
-
-
estrogen estrone formed from androstenedione by cytochrome P450 enzyme aromatase, estrogen is a mitogen for growth and development of hormone-dependent breast cancer
-
?
estrone sulfate + H2O
estrone + sulfate
-
-
-
?
estrone sulfate + H2O
estrone + sulfate
STS within the Leydig cells of Sus scrofa is involved in modulation of testicular estrogen bioavailability
-
-
?
estrone sulfate + H2O
estrone + sulfate
-
-
-
-
?
p-nitrophenyl-sulfate + H2O
p-nitrophenol + sulfate
-
arylsulfatase activity, EC 3.1.6.1, and various steroid sulfatase activities (EC 3.1.6.1) are functions of the same protein
-
-
?
p-nitrophenyl-sulfate + H2O
p-nitrophenol + sulfate
-
-
-
-
?
p-nitrophenyl-sulfate + H2O
p-nitrophenol + sulfate
-
arylsulfatase activity, EC 3.1.6.1, and various steroid sulfatase activities (EC 3.1.6.1) are functions of the same protein
-
-
?
p-nitrophenyl-sulfate + H2O
p-nitrophenol + sulfate
-
-
-
-
?
p-nitrophenyl-sulfate + H2O
p-nitrophenol + sulfate
-
arylsulfatase activity, EC 3.1.6.1, and various steroid sulfatase activities (EC 3.1.6.1) are functions of the same protein
-
-
?
p-nitrophenyl-sulfate + H2O
p-nitrophenol + sulfate
-
arylsulfatase activity, EC 3.1.6.1, and various steroid sulfatase activities (EC 3.1.6.1) are functions of the same protein
-
-
?
p-nitrophenyl-sulfate + H2O
p-nitrophenol + sulfate
-
arylsulfatase activity, EC 3.1.6.1, and various steroid sulfatase activities (EC 3.1.6.1) are functions of the same protein
-
-
?
p-nitrophenyl-sulfate + H2O
p-nitrophenol + sulfate
-
arylsulfatase activity, EC 3.1.6.1, and various steroid sulfatase activities (EC 3.1.6.1) are functions of the same protein
-
-
?
p-nitrophenyl-sulfate + H2O
p-nitrophenol + sulfate
-
arylsulfatase activity, EC 3.1.6.1, and various steroid sulfatase activities (EC 3.1.6.1) are functions of the same protein
-
-
?
pregnenolone 3-sulfate + H2O
pregnenolone + sulfate
-
-
-
?
pregnenolone 3-sulfate + H2O
pregnenolone + sulfate
-
-
-
?
pregnenolone 3-sulfate + H2O
pregnenolone + sulfate
-
-
-
-
?
pregnenolone sulfate + H2O
pregnenolone + sulfate
-
-
-
-
?
pregnenolone sulfate + H2O
pregnenolone + sulfate
-
-
-
-
?
pregnenolone sulfate + H2O
pregnenolone + sulfate
-
8.7% of the activity with cholesterol sulfate
-
-
?
steroid sulfate + H2O
steroid + sulfate
-
-
-
-
?
steroid sulfate + H2O
steroid + sulfate
-
steroid sulfatase converts all steroid sulfates into their free steroid forms
-
-
?
steroid sulfates + H2O
steroid + sulfate
-
also acts on some related steryl sulfates, phenol sulfates, steroid arylsulfates and steroid alkyl sulfates catalyzed at the same site
-
-
?
steroid sulfates + H2O
steroid + sulfate
-
also acts on some related steryl sulfates, phenol sulfates, steroid arylsulfates and steroid alkyl sulfates catalyzed at the same site
-
-
?
steroid sulfates + H2O
steroid + sulfate
-
also acts on some related steryl sulfates, phenol sulfates, steroid arylsulfates and steroid alkyl sulfates catalyzed at the same site
-
-
?
steroid sulfates + H2O
steroid + sulfate
-
also acts on some related steryl sulfates, phenol sulfates, steroid arylsulfates and steroid alkyl sulfates catalyzed at the same site
-
-
?
steroid sulfates + H2O
steroid + sulfate
-
also acts on some related steryl sulfates, phenol sulfates, steroid arylsulfates and steroid alkyl sulfates catalyzed at the same site
135595, 135598, 135599, 135600, 135601, 135602, 135603, 135604, 135605, 135606, 135611, 135612, 135614, 135615, 135616, 135617, 135619, 135622, 135624, 135625, 135626, 135628 -
-
?
steroid sulfates + H2O
steroid + sulfate
-
also acts on some related steryl sulfates, phenol sulfates, steroid arylsulfates and steroid alkyl sulfates catalyzed at the same site
-
-
?
steroid sulfates + H2O
steroid + sulfate
-
also acts on some related steryl sulfates, phenol sulfates, steroid arylsulfates and steroid alkyl sulfates catalyzed at the same site
-
-
?
steroid sulfates + H2O
steroid + sulfate
-
also acts on some related steryl sulfates, phenol sulfates, steroid arylsulfates and steroid alkyl sulfates catalyzed at the same site
-
-
?
steroid sulfates + H2O
steroid + sulfate
-
also acts on some related steryl sulfates, phenol sulfates, steroid arylsulfates and steroid alkyl sulfates catalyzed at the same site
-
-
?
steroid sulfates + H2O
steroid + sulfate
-
also acts on some related steryl sulfates, phenol sulfates, steroid arylsulfates and steroid alkyl sulfates catalyzed at the same site
-
-
?
steroid sulfates + H2O
steroid + sulfate
-
also acts on some related steryl sulfates, phenol sulfates, steroid arylsulfates and steroid alkyl sulfates catalyzed at the same site
-
-
?
testosterone 3-sulfate + H2O
testosterone + sulfate
-
-
-
?
testosterone 3-sulfate + H2O
testosterone + sulfate
-
-
-
?
testosterone 3-sulfate + H2O
testosterone + sulfate
-
-
-
-
?
additional information
?
-
-
NSS likely plays a key role in the regulation of the GABA-A receptor
-
-
?
additional information
?
-
-
-
-
-
?
additional information
?
-
-
biosynthesis of estrogens in breast tumor tissues of post-menopausal breast cancer patients, STS stimulates the growth and survival of estrogen-dependent breast tumors
-
-
?
additional information
?
-
-
ES is a component of the three-enzyme system that has been implicated in intracrine biosynthesis of estradiol, hence, proliferation of hormone-dependent breast tumors
-
-
?
additional information
?
-
-
in vivo the activity of STS in the mammary myoepithelial cells may influence the availability of active, unsulfated hormones to the adjacent epithelial cells within mammary tissue and may have a role in the regulation of mammary growth and development
-
-
?
additional information
?
-
-
steroid sulfatase in the fallopian tube may be involved in controlling the local steroid environment, which appears to regulate aspects of the physiological reproductive function of the fallopian tube
-
-
?
additional information
?
-
-
STS may play an important role within the CNS
-
-
?
additional information
?
-
-
STS stimulates steroid production and increases steroidogenic acute regulatory protein expression
-
-
?
additional information
?
-
-
the action of STS makes a major contribution to the in situ estrogen production in breast tumors
-
-
?
additional information
?
-
-
desulfates a number of 3beta-hydroxysteroid sulfates
-
-
?
additional information
?
-
-
enzyme may be involved in the quality of eggs in patients with endometriosis
-
-
?
additional information
?
-
-
no substrate: tibolone 17-sulfate
-
-
?
additional information
?
-
-
not: dichlorophenoxyethyl sulfate
-
-
?
additional information
?
-
-
not: androsterone 3-sulfate
-
-
?
additional information
?
-
-
higher activity for 16-unsubstituted than for 16alpha-hydroxylated substrates
-
-
?
additional information
?
-
-
not: 17-sulfate ester of beta-estradiol or delta4-androstene-3-one-17alpha-ol
-
-
?
additional information
?
-
-
-
-
-
?
additional information
?
-
-
ovarian estrogen synthesis, the relative contribution of STS activity to ovarian steroidogenesis is unclear but may have important physiological and pathophysiological implications
-
-
?
additional information
?
-
-
enzyme is responsible for the removal of the sulfamoyl group from oestrogen sulfamates
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(12aS)-N,N-dihydroxy-12a-methyl-1,3-dioxo-2-propyl-1,2,3,4,4a,4b,5,6,10b,11,12,12a-dodecahydronaphtho[2,1-f]isoquinoline-8-sulfinamide
-
-
(17beta)-17-(2,3,4,5,6-pentafluorobenzyl)-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-(2-furylmethyl)-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-(3,5-dibromobenzyl)-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-(3-benzyloxybenzyl)-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-(3-bromobenzyl)-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-(3-iodobenzyl)-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-(3-tert-butylbenzyl)-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-(3-trifluoromethylbenzyl)-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-(4-bromobenzyl)-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-(4-iodobenzyl)-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-(4-methyl-2-thienyl)-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-(4-tert-butylbenzyl)-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-(4-tert-butylbenzyl)estra-1(10),2,4-triene-3,17-diol
-
estradiol phenolic reversible inhibitor as reference, possible additional breast cancer therapy, no inhibition at 0.01 microM, at 0.1 microM 39% inhibition, at 1 microM 62% inhibition
(17beta)-17-(4-trifluoromethylbenzyl)-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-(cyclohexylmethyl)-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-(cyclopropylmethyl)-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-(pyridin-3-ylmethyl)-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-benzyl-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-benzylestra-1(10),2,4-triene-3,17-diol
-
estradiol phenolic reversible inhibitor as reference, possible additional breast cancer therapy, no inhibition at 0.01 microM, at 0.1 microM 15% inhibition, at 1 microM 48% inhibition
(17beta)-17-[3,5-bis(benzyloxy)benzyl]-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-[3,5-bis(tert-butyl)benzyl]-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-[3,5-bis(trifluoromethyl)benzyl]-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-[3-(dibenzylamino)benzyl]-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-[4-(benzyloxy)benzyl]-estra-1(10),2,4-triene-3,17-diol
-
-
(17beta)-17-{[2-(2-bromoethyl)cyclopropyl]methyl}estra-1(10),2,4-triene-3,17-diol
-
-
(17beta,17'beta)-17,17'-(2E)-but-2-ene-1,4-diylbisestra-1(10),2,4-triene-3,17-diol
-
reversible non-competitive or mixed inhibition, estradiol dimer with C17-C17 bond, possible additional breast cancer therapy, no inhibition at 0.01 microM, at 0.1 microM 42% inhibition, at 1 microM 56% inhibition
(17beta,17'beta)-17,17'-butane-1,4-diylbisestra-1(10),2,4-triene-3,17-diol
-
reversible non-competitive or mixed inhibition, estradiol dimer with C17-C17 bond, possible additional breast cancer therapy, no inhibition at 0.01 microM, at 0.1 microM 30% inhibition, at 1 microM 54% inhibition
(2-(1-adamantyl)-4-oxo-4H-chromen-6-yl)(oxo)acetic acid
-
-
(2-(1-adamantyl)-4-oxo-4H-chromen-6-yl)acetic acid
-
-
(p-O-sulfamoyl)-N-tetradecanoyl tyramine
(R)-1-[(4-cyanophenyl)(3-bromo-4-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole
pure R(+)-enantiomer of 1-[(4-Cyanophenyl)(3-bromo-4-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole
(S)-1-[(4-cyanophenyl)(3-bromo-4-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole
pure S(-)-enantiomer of 1-[(4-Cyanophenyl)(3-bromo-4-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole
1-indanone 4-O-sulfamate
-
-
1-indanone 5-O-sulfamate
-
-
1-indanone 6-O-sulfamate
-
-
1-tetralone 6-O-sulfamate
-
-
1-tetralone 7-O-sulfamate
-
-
1-[(4-cyanophenyl)(3-bromo-4-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole
bromo derivative of 1-[(4-cyanophenyl)(3-chloro-4-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole does improve aromatase inhibitory activity
1-[(4-cyanophenyl)(3-chloro-4-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole
meta-chloro derivative of 1-[(4-cyanophenyl)(4-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole does increase aromatase inhibition activity
1-[(4-cyanophenyl)(4-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole
increase of aromatase inhibitory activity due to presence of a para-cyanophenyl moiety
1-[bis-(3-bromo-4-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole
best dual inhibition
1-[bis-(3-sulfamoyloxy-4-methoxyphenyl)methyl]-1H-[1,2,4]triazole
methoxy groups reduce inhibition of aromatase compared to 1-[bis-(3-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole
1-[bis-(3-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole
sulfamate in meta-position increases aromatase inhibition strength compared to para-position
1-[bis-(4-sulfamoyloxy-3-methoxyphenyl)methyl]-1H-[1,2,4]triazole
exchange in positions of methoxy and sulfamate group compared to 1-[bis-(3-sulfamoyloxy-4-methoxyphenyl)methyl]-1H-[1,2,4]triazole fails to improve aromatase inhibitory activity
16alpha-hydroxydehydroepiandrosterone
-
competitive to dihydroepiandrosterone
17-oxoestra-1,3,5(10)-trien-3-yl sulfamate
17alpha-benzyl-17beta-hydroxyestra-1,3,5-(10)-triene-3-boronic acid
-
-
17alpha-benzyl-3,17beta-dihydroxyestra-1,3,5-(10)-triene
-
-
17beta estradiol
-
exposure to 17beta estradiol causes 70% reduction of estrone 3-sulfate sulfatase activity in MCF-7 cells after 6 days, but 9% increase in mammary myoepithelial cells
19,19-difluoro-17-oxo-4,9-cyclo-9,10-secoandrosta-1,3,5(10)-trien-1-yl hydrogen sulfate
-
-
19-fluoro-17-oxo-4,9-cyclo-9,10-secoandrosta-1,3,5(10)-trien-1-yl hydrogen sulfate
-
-
2',4'-dicyano-N,N-dihydroxybiphenyl-4-sulfinamide
-
-
2-(1-adamantyl)-4-oxo-4H-chromen-6-yl sulfamate
-
-
2-(1-adamantyl)-4-oxo-4H-chromene-6-carbaldehyde
-
-
2-(1-adamantyl)-4-oxo-4H-chromene-6-carboxamide
-
-
2-(1-adamantyl)-4-oxo-4H-chromene-6-carboxylic acid
-
-
2-(1-adamantyl)-4-oxo-4H-thiochromen-6-yl sulfamate
-
-
2-(1-adamantyl)-4-oxo-4H-thiochromene-6-carbonitrile
-
-
2-(1-adamantyl)-4-oxo-4H-thiochromene-6-carboxylic acid
-
-
2-(1-adamantyl)-6-(hydroxymethyl)-4H-chromen-4-one
-
-
2-(1-adamantyl)-6-glycoloyl-4H-chromen-4-one
-
-
2-(difluoromethyl)-17-oxoestra-1(10),2,4-trien-3-yl hydrogen sulfate
-
-
2-(fluoromethyl)-17-oxoestra-1(10),2,4-trien-3-yl hydrogen sulfate
-
-
2-bromo-4-[(R)-(4-cyanophenyl)(1H-1,2,4-triazol-1-yl)methyl]-N,N-dihydroxybenzenesulfinamide
-
-
2-chloro-4-[5-(2,6-difluoro-3-hydroxybenzoyl)thiophen-2-yl]phenyl sulfamate
dual inhibitor, acts both on STS and hydroxy steroid dehydrogenase 17beta-HSD1, reverses estrogen-induced T-47D cell proliferation
2-formyl-17alpha-benzyl-17beta-hydroxyestra-1,3,5(10)-triene
-
time- and concentration-dependent inhibitor, shows more or less pseudo-first order behavior at all concentrations
2-methoxy-6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate
-
-
2-methoxyestrone-3-O-sulfamate
-
potent active site-directed inhibitor, no effect on STS mRNA expression in fibroblasts
2-phenylindole sulfamate
-
2-phenylindole sulfamates with lipophilic side chains in 1- or 5-position of the indole with IC50-values between 2 nM and 0.001 mM, irreversibly inhibits hydrolysis of estrone sulfate in MDA-MB 231 cells, inhibits gene activation in estrogen receptor-positive MCF-7 breast cancer cells in submicromolar concentrations and reduces cell proliferation with IC50 of 0.001 mM
2-t-butyl-4H-1-benzopyran-4-one-6-boronic acid
-
-
2-tert-butyl-6-hydroxy-4H-chromen-4-one
-
-
2-[3-[[(4-[[(aminooxy)sulfinyl]oxy]phenyl)sulfanyl]methyl]-5-(1H-1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile
-
-
2H1-benzpyran 7-O-disulfamate
-
-
3'-((1H-1,2,4-triazol-1-yl)methyl)-3-chloro-4'-cyanobiphenyl-4-yl sulfamate
-
-
3'-((1H-1,2,4-triazol-1-yl)methyl)-3-chloro-5'-(2-cyanopropan-2-yl)biphenyl-4-yl sulfamate
-
68.2% inhibition at 0.01 mM
3'-((1H-1,2,4-triazol-1-yl)methyl)-3-chloro-5'-cyanobiphenyl-4-yl sulfamate
-
-
3'-((1H-1,2,4-triazol-1-yl)methyl)-3-chlorobiphenyl-4-yl sulfamate
-
-
3'-((1H-1,2,4-triazol-1-yl)methyl)-4'-cyanobiphenyl-4-yl sulfamate
-
-
3'-((1H-1,2,4-triazol-1-yl)methyl)biphenyl-4-yl sulfamate
-
-
3'-chloro-5-(1H-1,2,4-triazol-1-ylmethyl)biphenyl-2-carbonitrile
-
-
3,4,8-trimethylcoumarin 7-O-sulfamate
-
-
3,4-dihydro-4-methylcoumarin 7-O-sulfamate
-
-
3,4-dihydrocoumarin 7-O-sulfamate
-
-
3,4-dimethylcoumarin 7-O-sulfate
-
12-fold more potent than COUMATE
3-benzyl-4-methylcoumarin-7-O-sulfamate
-
IC50 value 0.68 nM in intact MCF-7 cells
3-hexyl-4-methylcoumarin-7-O-sulfamate
-
IC50 value 0.68 nM in intact MCF-7 cells
3-oxo-1,3-dihydro-2H-cyclobuta[c]chromen-6-yl sulfamate
-
-
3-sulfamoyloxy-N-(1''-pyridin-3''-ylmethyl)-16,17-seco-estra-1,3,5(10)-triene-16,17-imide
-
highly potent inhibitor, IC50: 1 nM, 18times more inhibitory than estrone-3-O-sulfamate, in vivo inhibition of STS
3-sulfamoyloxy-N-3,3,3-trifluoropropyl-16,17-seco-estra-1,3,4(10)-triene-16,17-imide
3-sulfamoyloxy-N-propyl-16,17-seco-estra-1,3,5(10)-triene-16,17-imide
-
highly potent inhibitor, IC50: 1 nM, 18times more inhibitory than estrone-3-O-sulfamate, in vivo inhibition of STS
3-[4-(3,4-difluoro-benzoylamino)-phenyl]-coumarin-7-O-sulfamate
compound exhibits poor cytotoxicity
3-[4-[2-(2,5-bis-trifluoromethyl-phenyl)-acetylamino]-phenyl]-coumarin-7-O-sulfamate
compound shows antiproliferative activity against the MCF-7 and T47D cell lines, GI50 value is 15.9 microM and 8.7 microM, respectively
4'-((1H-1,2,4-triazol-1-yl)methyl)-2'-cyanobiphenyl-4-yl sulfamate
-
-
4'-((1H-1,2,4-triazol-1-yl)methyl)-3-chloro-2'-cyanobiphenyl-4-yl sulfamate
-
-
4-(((4-cyanophenyl)(4H-1,2,4-triazol-4-yl)amino)methyl)-2-methoxyphenyl sulfamate
-
-
4-(cyclohexanecarboxamido)phenyl sulfamate
55.7% inhibition of isolated enzyme at 0.01 mM, 86.1% inhibition of the STS activity of JEG-3 carcinoma cells at 0.010 mM
4-(trifluoromethyl)coumarin 7-O-sulfamate
-
-
4-fluoro-17alpha-benzyl-17beta-hydroxyestra-1,3,5(10)-triene
-
linear mixed-type inhibition, compound is capable of binding at sites both within and outside the active site
4-fluoro-17beta-(3'-trifluoromethylbenzene)sulfonamideestra-1,3,5(10)-trien-3-ol
-
4-methylcoumarin 6,7-O,O-disulfamate
-
-
4-methylcoumarin 7-O-sulfamate
-
COUMATE, also in vivo
4-methylcoumarin-7-O-sulfamate
-
-
4-nitro-17beta-4'-biphenylsulfonamide-1,3,5(10)-estratrien-3-ol
-
4-oxo-1,2,3,4-tetrahydrocyclopenta[c]chromen-7-yl sulfamate
-
-
4-oxo-2,3-dihydro-1H-cyclopenta-[c][1]benzopyran-7-O-sulfamate
-
665 COUMATE, placental IC50: 200 nM
5'-((1H-1,2,4-triazol-1-yl)methyl)-2'-cyanobiphenyl-4-yl sulfamate
-
-
5'-((1H-1,2,4-triazol-1-yl)methyl)-3-chloro-2'-cyanobiphenyl-4-yl sulfamate
-
-
5,6,7,8-tetrahydronaphthalene 2-O-(N,N-dimethyl)sulfamate
-
-
5,6,7,8-tetrahydronaphthalene 2-O-(N-methyl)sulfamate
-
-
5,6,7,8-tetrahydronaphthalene 2-O-sulfamate
-
-
5-(((4-cyanophenyl)(4H-1,2,4-triazol-4-yl)amino)methyl)-2-methoxyphenyl sulfamate
-
-
5-((1H-1,2,4-triazol-1-yl)methyl)-3'-chloro-4'-hydroxybiphenyl-2-carbonitrile
-
-
5-((1H-1,2,4-triazol-1-yl)methyl)-4'-hydroxybiphenyl-2-carbonitrile
-
-
5-methyl-6-oxo-6,7,8,9,10,11-hexahydro-5H-cyclohepta[c]quinolin-3-yl sulfamate
-
-
5-pregnen-3beta,21-diol
-
most potent inhibitor of C21 steroids
5-pregnen-3beta,21-diol-20-one
-
most potent inhibitor of C21 steroids
5alpha-androstane-3alpha-17beta-diol
-
most potent inhibitor of C19 steroids
6-(3-phenylpropoxy)-8,9,10,11-tetrahydro-7H-cyclohepta[c]quinolin-3-yl sulfamate
-
-
6-(pentyloxy)-8,9,10,11-tetrahydro-7H-cyclohepta[c]quinolin-3-yl sulfamate
-
-
6-methoxy-8,9,10,11-tetrahydro-7H-cyclohepta[c]quinolin-3-yl sulfamate
-
-
6-methoxycoumarin 7-O-sulfamate
-
-
6-oxo-5-(3-phenylpropyl)-6,7,8,9,10,11-hexahydro-5H-cyclohepta[c]quinolin-3-yl sulfamate
-
-
6-oxo-5-pentyl-6,7,8,9,10,11-hexahydro-5H-cyclohepta[c]quinolin-3-yl sulfamate
-
-
6-oxo-6,7,8,9,10,11,12,13,14,15,16,17,18,19-tetradecahydrocyclopentadeca[c]chromen-3-yl sulfamate
-
-
6-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydrocyclotrideca[c]chromen-3-yl sulfamate
-
-
6-oxo-6,7,8,9,10,11,12,13,14,15-decahydrocycloundeca[c]chromen-3-yl sulfamate
-
-
6-oxo-6,7,8,9,10,11,12,13-octahydrocyclonona[c]chromen-3-yl sulfamate
-
-
6-oxo-6,7,8,9,10,11-hexahydro-5H-cyclohepta[c]quinolin-3-yl sulfamate
-
-
6-oxo-6,7,8,9,10,11-hexahydro-5H-cyclohepta[c]quinolin-3-ylsulfamide
-
-
6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-2-yl sulfamate
-
-
6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl dimethylsulfamate
-
-
6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate
6-oxo-7,8,9,10,11,12,13,14,15,16-decahydro-6H-cyclododeca[c]-chromen-3-yl sulfamate
-
-
6-oxo-7,8,9,10,11,12,13,14,15,16-decahydro-cyclododeca-[c][1]benzopyran-3-O-sulfamate
-
6612 COUMATE, placental IC50: 60 nM
6-oxo-7,8,9,10,11,12,13,14-octahydro-6H-cyclodeca[c]chromen-3-yl sulfamate
-
-
6-oxo-7,8,9,10,11,12,13,14-octahydro-cyclodeca-[c][1]benzopyran-3-O-sulfamate
-
6610 COUMATE, placental IC50: 1 nM
6-oxo-7,8,9,10,11,12-hexahydro-6H-cycloocta[c]chromen-3-yl sulfamate
-
i.e. STW64, treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer. Inhibitor almost completely blocks enzyme activity in peripheral blood lymphocytes and tumor tissues, inhibition is associated with significant reductions in serum concentrations of androstenediol and estrogens. Serum androstenedione concentration also decreases by up to 86%
6-oxo-7,8,9,10,11,12-hexahydro-cycloocta-[c][1]benzopyran-3-O-sulfamate
-
668 COUMATE, placental IC50: 30 nM
6-oxo-7,8,9,10-tetrahydro-6H-benzo[c]chromen-3-yl sulfamate
-
-
6-oxo-7,8,9,10-tetrahydro-dibenzo[b,d]pyran-3-O-sulfamate
-
666 COUMATE, placental IC50: 70 nM
6-oxo-8,9,10,11,12,13,14,15,16,17,18,19-dodecahydro-7H-cyclopentadeca-[c][1]benzopyran-3-O-sulfamate
-
6615 COUMATE, placental IC50: 370 nM, most potent tricyclic coumarin sulfamate inhibitor tested in vivo
6-oxo-8,9,10,11,12,13,14,15,16,17-decahydro-7H-cyclotrideca-[c][1]benzopyran-3-O-sulfamate
-
6613 COUMATE, placental IC50: 75 nM
6-oxo-8,9,10,11,12,13,14,15-octahydro-7H-cycloundeca-[c][1]benzopyran-3-O-sulfamate
-
6611 COUMATE, placental IC50: 13 nM
6-oxo-8,9,10,11,12,13-hexahydro-7H-cyclonona-[c][1]benzopyran-3-O-sulfamate
-
669 COUMATE, placental IC50: 2.4 nM
6-oxo-8,9,10,11-tetrahydro-7H-cyclohepta-[c][1]benzopyran-3-O-sulfamate
6-oxo-8,9,10,11-tetrahydro-7H-cylohepta-[c][1]benzopyran-boronic acid
-
-
667 COUMATE
-
i.e. 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta(c)chromen-3-yl sulfamate, coadministation of oestrone sulfamate and 667 COUMATE completely blocks enzyme activity and completely abrogates the ability of oestrone sulfamate to stimulate uterine growth
7,8-dihydronaphthalene 2-O-sulfamate
-
-
7-hydroxy-4-methylcoumarin 6-O-sulfamate
-
-
Ammonium molybdate
-
10 mM, 20% residual activity
calcium chloride
-
5 mM, 36% residual activity
cholesterol
-
1 mM, 57% inhibition
coumarin 7-O-sulfamate
-
-
cysteine
-
10 mM, 15% inhibition
daidzein-4'-O-sulfate
-
at 0.005 mM
daidzein-7,4'-di-O-sulfate
-
at 0.001 mM
dexamethasone
inhibits STS activity and expression in undifferentiated cells, the glucocorticoid antagonist RU486 reverses dexamethasone inhibition of STS
dithiothreitol
-
5 mM, 45% residual activity
EDTA
-
10% inhibition at 1 mM
estra-1,3,5-(10)-triene-17-one-3-boronic acid
-
competitive
estrone 3-O-sulfamate
-
-
estrone-3-O-(N,N-dimethyl)sulfamate
-
-
estrone-3-O-(N-methyl)sulfamate
-
-
estrone-3-O-methylthiophosphonate
-
-
glutathione
-
reduced form, 5 mM, 23.5% residual activity
human pituitary luteinizing hormone
-
human pituitary LH, reduces activity to 85% of baseline at 5 ng/ml, dose-dependent
-
interleukin-1beta
-
marked inhibition of mRNA expression and STS activity
-
KH2PO4
-
5 mM, 25% inhibition
KW-2581
-
active site-directed irreversible steroidal inhibitor
methyl 2-(1-adamantyl)-4-oxo-4H-chromene-6-carboxylate
-
-
N,N-dihydroxy-6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromene-3-sulfinamide
-
-
N,N-dimethoxy-6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromene-3-sulfinamide
-
-
N-acetylated estrone 3-O-sulfamate
-
inhibits the enzyme irreversibly, albeit much less potently than estrone 3-O-sulfamate
pregnenolone
-
1 mM, 10% inhibition
pregnenolone 3-sulfate
-
competitive inhibitor, dehydroepiandrosterone 3-sulfate as substrate
Rose bengal
-
histidine modification
STX289
-
N,N-dimethyl 667 COUMATE, analogue of STX64, inhibition 24 h after oral application: 0.1 mg/kg inhibits liver STS by 45%, skin STS by about 39%, 1 and 10 mg/kg inhibit liver STS completely, skin STS almost completely, inhibition 24 h after topical application to neck skin: 0.1 mg/kg inhibits skin and liver STS by <50%, remote skin STS by about 10%, 1and 10 mg/kg inhibit skin STS by 98%, remote skin STS by about 80 and more than 90% respectively, and liver STS by more than 80 and close by 100% respectively
sulfamic acid 2-bromo-4-(2-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)ethyl)phenyl ester
-
ethylene linker, based on phenol sulfamate pharmacophore (STS inhibition) incorporated into YM511 (aromatase inhibitor) scaffold
sulfamic acid 2-bromo-4-(3-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)propyl)phenyl ester
-
propylene linker, based on phenol sulfamate pharmacophore (STS inhibition) incorporated into YM511 (aromatase inhibitor) scaffold
sulfamic acid 2-bromo-4-[[(4-cyanophenyl)[1,2,4]triazol-4-ylamino]methyl]phenyl ester
sulfamic acid 2-chloro-4-(2-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)ethyl)phenyl ester
-
ethylene linker, based on phenol sulfamate pharmacophore (STS inhibition) incorporated into YM511 (aromatase inhibitor) scaffold
sulfamic acid 2-chloro-4-(2-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)ethylsulfanyl)phenyl ester
sulfamic acid 2-chloro-4-(3-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)propyl)phenyl ester
-
propylene linker, based on phenol sulfamate pharmacophore (STS inhibition) incorporated into YM511 (aromatase inhibitor) scaffold
sulfamic acid 3-(((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)methylsulfanyl)phenyl ester
-
thioether linker, based on phenol sulfamate pharmacophore (STS inhibition) incorporated into YM511 (aromatase inhibitor) scaffold
sulfamic acid 3-(2-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)-ethylsulfanyl)phenyl ester
-
thioether linker, based on phenol sulfamate pharmacophore (STS inhibition) incorporated into YM511 (aromatase inhibitor) scaffold
sulfamic acid 4-(((4-cyanophenyl)-(1,2,4)triazol-4-ylamino)methylsulfanyl)phenyl ester
-
thioether linker, , based on phenol sulfamate pharmacophore (STS inhibition) incorporated into YM511 (aromatase inhibitor) scaffold, best STS inhibitor of tested dual inhibitor compounds
sulfamic acid 4-((2-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)-ethyl)methylsulfamoyl)phenyl ester
-
N-methylated sulfonamide linker, based on phenol sulfamate pharmacophore (STS inhibition) incorporated into YM511 (aromatase inhibitor) scaffold
sulfamic acid 4-(10-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)decylsulfanyl)phenyl ester
-
thioether linker, based on phenol sulfamate pharmacophore (STS inhibition) incorporated into YM511 (aromatase inhibitor) scaffold
sulfamic acid 4-(2-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)-ethyl)phenyl ester
-
ethylene linker, based on phenol sulfamate pharmacophore (STS inhibition) incorporated into YM511 (aromatase inhibitor) scaffold
sulfamic acid 4-(2-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)-ethylsulfanylmethyl)phenyl ester
-
thioether linker, based on phenol sulfamate pharmacophore (STS inhibition) incorporated into YM511 (aromatase inhibitor) scaffold
sulfamic acid 4-(2-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)ethyl)-2-fluorophenyl ester
-
ethylene linker, based on phenol sulfamate pharmacophore (STS inhibition) incorporated into YM511 (aromatase inhibitor) scaffold
sulfamic acid 4-(3-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)-propyl)-2-fluorophenyl ester
-
propylene linker, based on phenol sulfamate pharmacophore (STS inhibition) incorporated into YM511 (aromatase inhibitor) scaffold
sulfamic acid 4-(3-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)propyl)phenyl ester
-
propylene linker, based on phenol sulfamate pharmacophore (STS inhibition) incorporated into YM511 (aromatase inhibitor) scaffold
sulfamic acid 4-(3-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)propylsulfanyl)phenyl ester
sulfamic acid 4-(5-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)pentylsulfanyl)phenyl ester
-
thioether linker, based on phenol sulfamate pharmacophore (STS inhibition) incorporated into YM511 (aromatase inhibitor) scaffold
sulfamic acid 5-[[(4-cyanophenyl)[1,2,4]triazol-4-ylamino]-methyl]-2-fluorophenyl ester
Sulfate esters
-
overview, e.g. p-nitrophenyl sulfate
-
tricyclic coumarin sulfamate
-
in vitro and in vivo inhibition studies with E1-STS from different tissues, structure-activity relationship of a number of tricyclic coumarin sulfamates, the size of the third ring has a marked effect on inhibitor potency
-
TX-1492
-
non-steroid Theramex compound, strong inhibitor, IC50: 22.5 nM in JEG-3 cells, 0.07 nM in MCF-7 cells
-
TX-1506
-
non-steroid Theramex compound, strong inhibitor, IC50: 11.9 nM in JEG-3 cells, 0.06 nM in MCF-7 cells
-
vanadium oxide(V)
-
50 mM, 51% residual activity
Zinc acetate
-
1.25 mM, 53% residual activity
(p-O-sulfamoyl)-N-tetradecanoyl tyramine
-
non-estrogenic STS inhibitor, IC50: 56 nM/l, anti-cancer activity
(p-O-sulfamoyl)-N-tetradecanoyl tyramine
-
DU-14, in vivo, increase in hippocampal acetylcholine
17-oxoestra-1,3,5(10)-trien-3-yl sulfamate
Haliotis sp.
-
-
17-oxoestra-1,3,5(10)-trien-3-yl sulfamate
-
-
17-oxoestra-1,3,5(10)-trien-3-yl sulfamate
-
-
3-nitrophenyl sulfamate
Haliotis sp.
-
-
3-nitrophenyl sulfamate
-
-
3-nitrophenyl sulfamate
-
-
3-sulfamoyloxy-N-3,3,3-trifluoropropyl-16,17-seco-estra-1,3,4(10)-triene-16,17-imide
highly potent, long-acting, nonestrogenic steroid sulfatase inhibitor with inhibitory properties to human carbonic anhydrase II, thus enabling transport by erythorcytes, no estrogenic effects observed in uterine weight gain study with ovariectomized Wistar rats, 24 h after last dose of 4 days of oral administration of 10 mg/kg/d, in vivo: single dose of 0.1 mg/kg 48% inhibition of liver steroid sulfatase activity, 0.5 and 1 mg/kg total inhibition, activity measured 24 h after dose administration, recovery of steroid sulfatase acitivity after single oral dose of 10 mg/kg: complete inhibition till day 5, day 17: 50% recovery, day 28: complete recovery
3-sulfamoyloxy-N-3,3,3-trifluoropropyl-16,17-seco-estra-1,3,4(10)-triene-16,17-imide
-
highly potent, long-acting, nonestrogenic steroid sulfatase inhibitor with inhibitory properties to human carbonic anhydrase II, thus enabling transport by erythorcytes, no estrogenic effects observed in uterine weight gain study with ovariectomized Wistar rats, 24 h after last dose of 4 days of oral administration of 10 mg/kg/d, in vivo: single dose of 0.1 mg/kg 48% inhibition of liver steroid sulfatase activity, 0.5 and 1 mg/kg total inhibition, activity measured 24 h after dose administration, recovery of steroid sulfatase acitivity after single oral dose of 10 mg/kg: complete inhibition till day 5, day 17: 50% recovery, day 28: complete recovery
6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate
Haliotis sp.
-
-
6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate
-
-
6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate
-
-
6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate
-
-
6-oxo-8,9,10,11-tetrahydro-7H-cyclohepta-[c][1]benzopyran-3-O-sulfamate
-
6,6,7-COUMATE, IC50: 5.1 nM in JEG-3 cells, 0.43 nM in MCF-7 cells
6-oxo-8,9,10,11-tetrahydro-7H-cyclohepta-[c][1]benzopyran-3-O-sulfamate
-
667 COUMATE, placental IC50: 8 nM
6-oxo-8,9,10,11-tetrahydro-7H-cyclohepta-[c][1]benzopyran-3-O-sulfamate
-
6,6,7-COUMATE, potent inhibitor, in vivo inhibition study, more inhibitory than TX-1299
AgNO3
-
5 mM, 65% inhibition
CN-
-
-
dehydroepiandrosterone
-
competitive to 16alpha-hydroxydehydroepiandrosterone
dehydroepiandrosterone
-
-
Estrone 3-sulfate
-
competitive inhibitor
estrone-3-O-sulfamate
-
active site-directed inhibitor; EMATE, most potent, irreversible
estrone-3-O-sulfamate
-
EMATE, most potent, irreversible
estrone-3-O-sulfamate
-
active site-directed inhibitor; EMATE, most potent, irreversible
estrone-3-O-sulfamate
-
active site-directed inhibitor; also in vivo; EMATE, most potent, irreversible
estrone-3-O-sulfamate
-
potent inhibitor, dose-dependent, maximum inhibition between 100 and 1000 nM
estrone-3-O-sulfamate
-
specific inhibitor, concentration-dependent, complete inhibition at 0.1 mM, 100 nM and 10 nM, 89% inhibition at 1 nM
estrone-3-O-sulfamate
-
-
estrone-3-O-sulfamate
-
highly potent, specific STS inhibitor, complete inhibition at 0.001 mM
estrone-3-O-sulfamate
-
-
estrone-3-sulfamate
-
best inhibitor, IC50: 3.2 nM in JEG-3 cells, 0.08 nM in MCF-7 cells
estrone-3-sulfamate
-
potent estrone sulfatase inhibitor that causes irreversible inactivation of the enzyme
Fe2+
10 mM, about 50% of initial activity
Fe2+
10 mM, about 40% of initial activity
irosustat
-
i.e. STX64, BN83495, structure-activity relationship study. The inhibitor is used in clinical trials for patients with advanced hormone-dependent cancer
Na-tetraborate
-
-
Na2B4O7
-
-
Na2SO3
-
5 mM, 43% inhibition
Na2SO4
-
5 mM, 18% inhibition
p-Nitrophenyl sulfate
-
-
p-Nitrophenyl sulfate
-
-
p-Nitrophenyl sulfate
-
noncompetitive inhibitor, dehydroepiandrosterone 3-sulfate as substrate
p-Nitrophenyl sulfate
-
-
p-Nitrophenyl sulfate
-
-
p-Nitrophenyl sulfate
-
-
p-Nitrophenyl sulfate
-
-
p-Nitrophenyl sulfate
-
-
phosphate
Haliotis sp.
-
abalone sulfatases is inhibited by phosphate buffer: 15% activity in 5 mM K2HPO4/KH2PO4, pH 7
phosphate
-
limpet sulfatase is inhibited by phosphate buffer: 4% activity in 5 mM K2HPO4/KH2PO4, pH 7
Steroids
-
overview, e.g. estrone, estradiol, C21 steroids, C19 steroids
Steroids
-
overview, e.g. estrone, estradiol, C21 steroids, C19 steroids
STX213
-
phenol sulfamate pharmacophore, irreversible total inhibition from 10-1000 nM in Ishikawa cells, in vivo: upon administration of 1 mg/kg body mass/day reduced tumor growth over 28-day period in transplanted Ishikawa cells in MF-1 nude ovariectomized mice in the presence of estradiol sulfate (prerequisite for tumor cell development in ovariectomized mice), abolished liver STS activity, and reduced plasma estradiol levels
STX213
highly potent, long-acting, nonestrogenic steroid sulfatase inhibitor with inhibitory properties to human carbonic anhydrase II, thus enabling transport by erythorcytes, no estrogenic effects observed in uterine weight gain study with ovariectomized Wistar rats, 24 h after last dose of 4 days of oral administration of 10 mg/kg/d, in vivo: single dose of 0.1 mg/kg 25% inhibition of liver steroid sulfatase activity, 0.5 and 1 mg/kg total inhibition, activity measured 24 h after dose administration, recovery of steroid sulfatase acitivity after single oral dose of 10 mg/kg: complete inhibition till day 4, day 12: 50% recovery, day 15: almost complete recovery
STX213
-
highly potent, long-acting, nonestrogenic steroid sulfatase inhibitor with inhibitory properties to human carbonic anhydrase II, thus enabling transport by erythorcytes, no estrogenic effects observed in uterine weight gain study with ovariectomized Wistar rats, 24 h after last dose of 4 days of oral administration of 10 mg/kg/d, in vivo: single dose of 0.1 mg/kg 25% inhibition of liver steroid sulfatase activity, 0.5 and 1 mg/kg total inhibition, activity measured 24 h after dose administration, recovery of steroid sulfatase acitivity after single oral dose of 10 mg/kg: complete inhibition till day 4, day 12: 50% recovery, day 15: almost complete recovery
STX64
0.0001 mM, 88.3% inhibition
STX64
-
synonym BN83495, phenol sulfamate pharmacophore, irreversible STS inhibition from 10-1000 nM in Ishikawa cells, irreversible inhibition in OVCAR-3 ovarian cancer cells and JEG-3 choriocarcionoma cells at 10µM, irreversible inhibition from 10-1000 nM in LNCaP prostate cancer cells, in vivo: upon administration of 1 mg/kg body mass/day reduced tumor growth over 28-day period in transplanted Ishikawa cells in MF-1 nude ovariectomized mice in the presence of estradiol sulfate (prerequisite for tumor cell development in ovariectomized mice), abolished liver STS activity, and reduced plasma estradiol levels
STX64
-
strong STS inhibitor with phenol sulfamate pharmacophore, basis for STS inhibition in dual inhibitors in scaffold of aromatase inhibitor YM511
STX64
-
synonyms BN83495 or 667Coumate, 1 mg/kg/day given orally, treatment starting at Ishikawa cell tumor size of about 100 cubic mm (intact mice): no significant tumor growth reduction after 35 days of inhibitor treatment. Estradiol sulfate stimulated tumor growth of Ishikawa cells in ovariectomized mice, results after day 28 of inhibitor treatment: 1 mg/kg/day given orally reduces tumor growth by 48%, complete Ishikawa cell tumor STS inhibition, 1 mg/kg given orally once weekly: no tumor growth inhibition, no tumor STS inhibition, 10 mg/kg/day given orally: tumor growth inhibition by 59%, complete tumor STS inhibition
STX64
synonym BN83495, irreversible inhibition, STS inhibitor property within dual aromatase-sulfatase inhibitor, letrozole reversible cytochrome P450 enzyme aromatase inhibitor serves as aromatase inhibiting component
STX64
-
i.e. 667 Coumate or BN83495
STX64
-
synonym BN83495, inhibition 24 h after oral application: 0.1 mg/kg body mass inhibits liver STS by 79%, skin STS by about 59%, 1 and 10 mg/kg inhibitis liver STS activity completely, skin STS almost completely, inhibition 24 h after topical application to neck skin: 0.1 mg/kg inhibits skin STS by 95%, remote skin STS by about 33%, liver STS by 45%, 1 and 10 mg/kg inhibits skin STS by 99%, remote skin STS almost completely, and liver STS by about 90%
STX64
-
synonyms BN83495 or 667Coumate, estradiol sulfate stimulates tumor growth of Ishikawa cells in ovariectomized mice, results after day 28 of inhibitor treatment: 1 mg/kg/day given orally completely inhibits mouse liver STS acitivity, and reduces plasma estradiol by 63%, 1 mg/kg given orally and once weekly inhibits liver STS activity by about 40%, no plasma estradiol reduction, 10 mg/kg given orally and once weekly: complete inhibition of liver STS, and reduction of plasma estradiol by 93%
sulfamic acid 2-bromo-4-[[(4-cyanophenyl)[1,2,4]triazol-4-ylamino]methyl]phenyl ester
-
dual aromatase-sulfatase inhibitor, IC50 value for aromatase 0.82 nM
sulfamic acid 2-bromo-4-[[(4-cyanophenyl)[1,2,4]triazol-4-ylamino]methyl]phenyl ester
-
dual aromatase-sulfatase inhibitor. Alomst complete inhibition of both aromates and sulfatase in pregnant mare's serum gonadotropin pretreated female rats 3 h after a single oral dose. No inhibition of aldosterone synthesis
sulfamic acid 2-chloro-4-(2-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)ethylsulfanyl)phenyl ester
-
thioether linker based on phenol sulfamate pharmacophore (STS inhibition) incorporated into YM511 (aromatase inhibitor) scaffold
sulfamic acid 2-chloro-4-(2-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)ethylsulfanyl)phenyl ester
-
based on phenol sulfamate pharmacophore (STS inhibition) incorporated into YM511 (aromatase inhibitor) scaffold, best dual inhibition performance in vivo in female Wistar rats: inhibition 3 h after single oral dose of 10 mg/kg body mass: 92% for aromatase, 98% for STS
sulfamic acid 4-(3-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)propylsulfanyl)phenyl ester
-
thioether linker, based on phenol sulfamate pharmacophore (STS inhibition) incorporated into YM511 (aromatase inhibitor) scaffold
sulfamic acid 4-(3-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)propylsulfanyl)phenyl ester
-
based on phenol sulfamate pharmacophore (STS inhibition) incorporated into YM511 (aromatase inhibitor) scaffold, dual inhibition performance in vivo in female Wistar rats: inhibition 3 h after single oral dose of 10 mg/kg body mass: 82% for aromatase, 85% for STS
sulfamic acid 5-[[(4-cyanophenyl)[1,2,4]triazol-4-ylamino]-methyl]-2-fluorophenyl ester
-
dual aromatase-sulfatase inhibitor, IC50 value for aromatase 0.77 nM
sulfamic acid 5-[[(4-cyanophenyl)[1,2,4]triazol-4-ylamino]-methyl]-2-fluorophenyl ester
-
dual aromatase-sulfatase inhibitor. Potent inhibition of both aromates and sulfatase in pregnant mare's serum gonadotropin pretreated female rats 3 h after a single oral dose
TX-1299
-
non-steroid Theramex compound, strong inhibitor, IC50: 5.3 nM in JEG-3 cells, 0.76 nM in MCF-7 cells
-
TX-1299
-
non-steroid Theramex compound, potent inhibitor, in vivo inhibition study, 80% as inhibitory as 6,6,7-COUMATE
-
Zn2+
10 mM, loss of activity
Zn2+
10 mM, loss of activity
additional information
-
not inhibited by estrone, dehydroepiandrosterone, alkaline phosphatase treatment and phosphohydrolase inhibitors
-
additional information
-
not inhibited by danazol or letrozole
-
additional information
-
not inhibitory: phosphate, sulfate, sulfide
-
additional information
-
not inhibited by letrozole, 5'-((1H-1,2,4-triazol-1-yl)methyl)-2'-cyanobiphenyl-4-yl dimethylsulfamate, 5'-((1H-1,2,4-triazol-1-yl)methyl)-3-chloro-2'-cyanobiphenyl-4-yl dimethylsulfamate, 5'-((1H-1,2,4-triazol-1-yl)methyl)-4-chloro-2'-cyanobiphenyl-3-yl sulfamate, 3'-((1H-1,2,4-triazol-1-yl)methyl)-4'-cyanobiphenyl-3-yl sulfamate, 3'-((1H-1,2,4-triazol-1-yl)methyl)-5'-cyanobiphenyl-4-yl sulfamate, 2'-((1H-1,2,4-triazol-1-yl)methyl)-3-chloro-5'-cyanobiphenyl-4-yl sulfamate, and 3'-((1H-1,2,4-triazol-1-yl)methyl)-5'-(2-cyanopropan-2-yl)biphenyl-4-yl sulfamate
-
additional information
-
evaluation of quinolin-2(1H)-one and quinoline derivatives of irosustat as enzyme inhibitors. N-(piperidino), N,N-(dibenzyl)sulfamate, and N,N-dimethyl derivatives of estrone 3-O-sulfamate are weak reversible or inactive inhibitors of the enzyme in placental microsomes. No inhibition by the N-benzoyl estrone 3-O-sulfamate variant 3-(benzyloxy)-8,9,10,11-tetrahydro-5H-cyclohepta[c]quinolin-6(7H)-one. Molecular modelling
-
additional information
-
design and synthesis of steroidal and nonsteroidal enzyme inhibitors as sulfamate derivatives and nonsulfamate derivatives, overview
-
additional information
-
sulfamoyloxy-substituted 2-phenylindoles are developed as antiestrogen-based inhibitors of estrone sulfatase. A series of compounds that can inhibit both aromatase and sulfatase is developed based on the structure of estrone 3-sulfamate, a typical estrone sulfatase inhibitor; synthesis and in vitro evaluation of the inhibitory potency of an extended series of 17alpha derivatives of estradiol, structure-activity relationship study, overview
-
additional information
-
inhibitor development of the enzyme in cancer treatment, clinical studies, overview
-
additional information
design of sulfated steroid inhibitors. The presence of a NO2 or Br at the 2-position of the A-ring results in a decrease in potency compared to their A-ring-unsubstituted counterparts. The presence of a nitro group or fluorine atom at the 4-position of the A-ring results in an increase in potency
-
additional information
-
STS inhibitors were developed to treat breast cancer but could also used to treat endometriosis, polycystic ovarian disease, prostate cancer, and some androgen-dependent skin conditions, such as acne and hirsutism
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.004633
(R)-1-[(4-cyanophenyl)(3-bromo-4-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole
Homo sapiens
enzyme activity in JEG-3 cells, IC50 for aromatase = 0.0000032 mM
0.000553
(S)-1-[(4-cyanophenyl)(3-bromo-4-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole
Homo sapiens
enzyme activity in JEG-3 cells, IC50 for aromatase = 0.0000143 mM
0.0026
1-[(4-cyanophenyl)(3-bromo-4-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole
Homo sapiens
enzyme activity in JEG-3 cells, IC50 for aromatase = 0.000003 mM
0.00092
1-[(4-cyanophenyl)(3-chloro-4-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole
Homo sapiens
enzyme activity in JEG-3 cells, IC50 for aromatase = 0.000012 mM
0.000476
1-[bis-(3-bromo-4-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole
Homo sapiens
enzyme activity in JEG-3 cells, IC50 for aromatase = 0.000043 mM
0.0000163
2',4'-dicyano-N,N-dihydroxybiphenyl-4-sulfinamide
Homo sapiens
-
-
0.0000159
2-chloro-4-[5-(2,6-difluoro-3-hydroxybenzoyl)thiophen-2-yl]phenyl sulfamate
Homo sapiens
whole cell assay, pH not specified in the publication, temperature not specified in the publication
0.000078
2-methoxy-6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate
Homo sapiens
-
in JEG-3 cells, pH not specified in the publication, temperature not specified in the publication
0.001
2-phenylindole sulfamate
Homo sapiens
-
2-phenylindole sulfamates with lipophilic side chains in 1- or 5-position of the indole with IC50-values between 2 nM and 0.001 mM, irreversibly inhibits hydrolysis of estrone sulfate in MDA-MB 231 cells, inhibits gene activation in estrogen receptor-posi
0.086
2-t-butyl-4H-1-benzopyran-4-one-6-boronic acid
Homo sapiens
-
30°C, pH 7.0
0.0000326
3'-((1H-1,2,4-triazol-1-yl)methyl)-3-chloro-4'-cyanobiphenyl-4-yl sulfamate
Homo sapiens
-
-
0.006333
3'-((1H-1,2,4-triazol-1-yl)methyl)-3-chloro-5'-cyanobiphenyl-4-yl sulfamate
Homo sapiens
-
-
0.00016
3'-((1H-1,2,4-triazol-1-yl)methyl)-3-chlorobiphenyl-4-yl sulfamate
Homo sapiens
-
-
0.00014
3'-((1H-1,2,4-triazol-1-yl)methyl)-4'-cyanobiphenyl-4-yl sulfamate
Homo sapiens
-
-
0.0055
3'-((1H-1,2,4-triazol-1-yl)methyl)biphenyl-4-yl sulfamate
Homo sapiens
-
-
0.032
3-benzyl-4-methylcoumarin-7-O-sulfamate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.008
3-hexyl-4-methylcoumarin-7-O-sulfamate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000032
3-oxo-1,3-dihydro-2H-cyclobuta[c]chromen-6-yl sulfamate
Homo sapiens
-
in JEG-3 cells, pH not specified in the publication, temperature not specified in the publication
0.000001
3-sulfamoyloxy-N-(1''-pyridin-3''-ylmethyl)-16,17-seco-estra-1,3,5(10)-triene-16,17-imide
Rattus norvegicus
-
highly potent inhibitor, IC50: 1 nM, 18times more inhibitory than estrone-3-O-sulfamate, in vivo inhibition of STS
0.000000035
3-sulfamoyloxy-N-3,3,3-trifluoropropyl-16,17-seco-estra-1,3,4(10)-triene-16,17-imide
0.000001
3-sulfamoyloxy-N-propyl-16,17-seco-estra-1,3,5(10)-triene-16,17-imide
Rattus norvegicus
-
highly potent inhibitor, IC50: 1 nM, 18times more inhibitory than estrone-3-O-sulfamate, in vivo inhibition of STS
0.00018
3-[4-(3,4-difluoro-benzoylamino)-phenyl]-coumarin-7-O-sulfamate
Homo sapiens
pH 7.4, 37°C
0.0018
3-[4-[2-(2,5-bis-trifluoromethyl-phenyl)-acetylamino]-phenyl]-coumarin-7-O-sulfamate
Homo sapiens
pH 7.4, 37°C
0.0000286
4'-((1H-1,2,4-triazol-1-yl)methyl)-2'-cyanobiphenyl-4-yl sulfamate
Homo sapiens
-
-
0.00005
4'-((1H-1,2,4-triazol-1-yl)methyl)-3-chloro-2'-cyanobiphenyl-4-yl sulfamate
Homo sapiens
-
-
0.00038
4-(((4-cyanophenyl)(4H-1,2,4-triazol-4-yl)amino)methyl)-2-methoxyphenyl sulfamate
Homo sapiens
-
-
0.00004
4-fluoro-17alpha-benzyl-17beta-hydroxyestra-1,3,5(10)-triene
Homo sapiens
-
pH 7.0, temperature not specified in the publication
2.5
4-fluoro-17beta-(3'-trifluoromethylbenzene)sulfonamideestra-1,3,5(10)-trien-3-ol
Homo sapiens
pH 7.4, 24°C
1
4-nitro-17beta-4'-biphenylsulfonamide-1,3,5(10)-estratrien-3-ol
Homo sapiens
pH 7.4, 24°C
0.000007
4-oxo-1,2,3,4-tetrahydrocyclopenta[c]chromen-7-yl sulfamate
Homo sapiens
-
in JEG-3 cells, pH not specified in the publication, temperature not specified in the publication
0.0002
4-oxo-2,3-dihydro-1H-cyclopenta-[c][1]benzopyran-7-O-sulfamate
Rattus norvegicus
-
665 COUMATE, placental IC50: 200 nM
0.000035
5'-((1H-1,2,4-triazol-1-yl)methyl)-2'-cyanobiphenyl-4-yl sulfamate
Homo sapiens
-
-
0.0000055
5'-((1H-1,2,4-triazol-1-yl)methyl)-3-chloro-2'-cyanobiphenyl-4-yl sulfamate
Homo sapiens
-
-
0.01
5-(((4-cyanophenyl)(4H-1,2,4-triazol-4-yl)amino)methyl)-2-methoxyphenyl sulfamate
Homo sapiens
-
-
0.0024
5-methyl-6-oxo-6,7,8,9,10,11-hexahydro-5H-cyclohepta[c]quinolin-3-yl sulfamate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0016
6-oxo-6,7,8,9,10,11,12,13,14,15,16,17,18,19-tetradecahydrocyclopentadeca[c]chromen-3-yl sulfamate
Homo sapiens
-
in JEG-3 cells, pH not specified in the publication, temperature not specified in the publication
0.00022
6-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydrocyclotrideca[c]chromen-3-yl sulfamate
Homo sapiens
-
in JEG-3 cells, pH not specified in the publication, temperature not specified in the publication
0.000000015
6-oxo-6,7,8,9,10,11,12,13,14,15-decahydrocycloundeca[c]chromen-3-yl sulfamate
Homo sapiens
-
in JEG-3 cells, pH not specified in the publication, temperature not specified in the publication
0.000000022
6-oxo-6,7,8,9,10,11,12,13-octahydrocyclonona[c]chromen-3-yl sulfamate
Homo sapiens
-
in JEG-3 cells, pH not specified in the publication, temperature not specified in the publication
0.00024
6-oxo-6,7,8,9,10,11-hexahydro-5H-cyclohepta[c]quinolin-3-yl sulfamate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.001
6-oxo-6,7,8,9,10,11-hexahydro-5H-cyclohepta[c]quinolin-3-ylsulfamide
Homo sapiens
-
above, pH not specified in the publication, temperature not specified in the publication
0.000283
6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-2-yl sulfamate
Homo sapiens
-
in JEG-3 cells, pH not specified in the publication, temperature not specified in the publication
0.01
6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl dimethylsulfamate
Homo sapiens
-
above, in JEG-3 cells, pH not specified in the publication, temperature not specified in the publication
0.0000015
6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate
Homo sapiens
-
in JEG-3 cells, pH not specified in the publication, temperature not specified in the publication
0.0001
6-oxo-7,8,9,10,11,12,13,14,15,16-decahydro-6H-cyclododeca[c]-chromen-3-yl sulfamate
Homo sapiens
-
in JEG-3 cells, pH not specified in the publication, temperature not specified in the publication
0.00006
6-oxo-7,8,9,10,11,12,13,14,15,16-decahydro-cyclododeca-[c][1]benzopyran-3-O-sulfamate
Rattus norvegicus
-
6612 COUMATE, placental IC50: 60 nM
0.000000025
6-oxo-7,8,9,10,11,12,13,14-octahydro-6H-cyclodeca[c]chromen-3-yl sulfamate
Homo sapiens
-
in JEG-3 cells, pH not specified in the publication, temperature not specified in the publication
0.000001
6-oxo-7,8,9,10,11,12,13,14-octahydro-cyclodeca-[c][1]benzopyran-3-O-sulfamate
Rattus norvegicus
-
6610 COUMATE, placental IC50: 1 nM
0.00003
6-oxo-7,8,9,10,11,12-hexahydro-cycloocta-[c][1]benzopyran-3-O-sulfamate
Rattus norvegicus
-
668 COUMATE, placental IC50: 30 nM
0.0000009
6-oxo-7,8,9,10-tetrahydro-6H-benzo[c]chromen-3-yl sulfamate
Homo sapiens
-
in JEG-3 cells, pH not specified in the publication, temperature not specified in the publication
0.00007
6-oxo-7,8,9,10-tetrahydro-dibenzo[b,d]pyran-3-O-sulfamate
Rattus norvegicus
-
666 COUMATE, placental IC50: 70 nM
0.00037
6-oxo-8,9,10,11,12,13,14,15,16,17,18,19-dodecahydro-7H-cyclopentadeca-[c][1]benzopyran-3-O-sulfamate
Rattus norvegicus
-
6615 COUMATE, placental IC50: 370 nM, most potent tricyclic coumarin sulfamate inhibitor tested in vivo
0.000075
6-oxo-8,9,10,11,12,13,14,15,16,17-decahydro-7H-cyclotrideca-[c][1]benzopyran-3-O-sulfamate
Rattus norvegicus
-
6613 COUMATE, placental IC50: 75 nM
0.000013
6-oxo-8,9,10,11,12,13,14,15-octahydro-7H-cycloundeca-[c][1]benzopyran-3-O-sulfamate
Rattus norvegicus
-
6611 COUMATE, placental IC50: 13 nM
0.0000024
6-oxo-8,9,10,11,12,13-hexahydro-7H-cyclonona-[c][1]benzopyran-3-O-sulfamate
Rattus norvegicus
-
669 COUMATE, placental IC50: 2.4 nM
0.00000043 - 0.000008
6-oxo-8,9,10,11-tetrahydro-7H-cyclohepta-[c][1]benzopyran-3-O-sulfamate
0.171
6-oxo-8,9,10,11-tetrahydro-7H-cylohepta-[c][1]benzopyran-boronic acid
Homo sapiens
-
30°C, pH 7.0
0.0000029
667-coumate
Homo sapiens
-
37°C
0.00000008 - 0.0000032
estrone-3-sulfamate
0.000015
KW-2581
Homo sapiens
-
37°C
0.0000015
N,N-dihydroxy-6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromene-3-sulfinamide
Homo sapiens
-
-
0.0000015 - 0.000008
STX64
0.0061
sulfamic acid 2-bromo-4-(2-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)ethyl)phenyl ester
Homo sapiens
-
inhibition of STS activity in JEG-3 cells tested with concentrations of 0.001-10000 nmol/l, IC50 for aromatase = 0.000001 mM
0.0055
sulfamic acid 2-bromo-4-(3-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)propyl)phenyl ester
Homo sapiens
-
inhibition of STS activity in JEG-3 cells tested with concentrations of 0.001-10000 nmol/l, IC50 for aromatase = 0.0000015 mM
0.000039
sulfamic acid 2-bromo-4-[[(4-cyanophenyl)[1,2,4]triazol-4-ylamino]methyl]phenyl ester
Homo sapiens
-
-
0.0015
sulfamic acid 2-chloro-4-(2-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)ethyl)phenyl ester
Homo sapiens
-
inhibition of STS activity in JEG-3 cells tested with concentrations of 0.001-10000 nmol/l, IC50 for aromatase = 0.0000017 mM
0.0012
sulfamic acid 2-chloro-4-(2-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)ethylsulfanyl)phenyl ester
Homo sapiens
-
inhibition of STS activity in JEG-3 cells tested with concentrations of 0.001-10000 nmol/l, IC50 for aromatase = 0.00000045 mM
0.0015
sulfamic acid 2-chloro-4-(3-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)propyl)phenyl ester
Homo sapiens
-
inhibition of STS activity in JEG-3 cells tested with concentrations of 0.001-10000 nmol/l, IC50 for aromatase = 0.0000021 mM
0.0035
sulfamic acid 3-(((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)methylsulfanyl)phenyl ester
Homo sapiens
-
inhibition of STS activity in JEG-3 cells tested with concentrations of 0.001-10000 nmol/l, IC50 for aromatase = 0.0000039 mM
0.01
sulfamic acid 3-(2-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)-ethylsulfanyl)phenyl ester
Homo sapiens
-
larger than 0.01 mM, inhibition of STS activity in JEG-3 cells tested with concentrations of 0.001-10000 nmol/l, IC50 for aromatase = 0.0000017 mM
0.0009
sulfamic acid 4-(((4-cyanophenyl)-(1,2,4)triazol-4-ylamino)methylsulfanyl)phenyl ester
Homo sapiens
-
inhibition of STS activity in JEG-3 cells tested with concentrations of 0.001-10000 nmol/l, IC50 for aromatase = 0.0000055 mM, best STS inhibitor of tested dual inhibitors
0.01
sulfamic acid 4-((2-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)-ethyl)methylsulfamoyl)phenyl ester
Homo sapiens
-
larger than 0.01 mM, inhibition of STS activity in JEG-3 cells tested with concentrations of 0.001-10000 nmol/l, IC50 for aromatase = 0.00001 mM
0.0019
sulfamic acid 4-(10-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)decylsulfanyl)phenyl ester
Homo sapiens
-
inhibition of STS activity in JEG-3 cells tested with concentrations of 0.001-10000 nmol/l, IC50 for aromatase = 0.0000055 mM
0.01
sulfamic acid 4-(2-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)-ethyl)phenyl ester
Homo sapiens
-
larger than 0.01 mM, inhibition of STS activity in JEG-3 cells tested with concentrations of 0.001-10000 nmol/l, IC50 for aromatase = 0.0000021 mM
0.01
sulfamic acid 4-(2-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)-ethylsulfanylmethyl)phenyl ester
Homo sapiens
-
larger than 0.01 mM, inhibition of STS activity in JEG-3 cells tested with concentrations of 0.001-10000 nmol/l, IC50 for aromatase = 0.00000037 mM
0.0026
sulfamic acid 4-(2-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)ethyl)-2-fluorophenyl ester
Homo sapiens
-
inhibition of STS activity in JEG-3 cells tested with concentrations of 0.001-10000 nmol/l, IC50 for aromatase = 0.000002 mM
0.0016
sulfamic acid 4-(3-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)-propyl)-2-fluorophenyl ester
Homo sapiens
-
inhibition of STS activity in JEG-3 cells tested with concentrations of 0.001-10000 nmol/l, IC50 for aromatase = 0.0000025 mM
0.01
sulfamic acid 4-(3-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)propyl)phenyl ester
Homo sapiens
-
larger than 0.01 mM, inhibition of STS activity in JEG-3 cells tested with concentrations of 0.001-10000 nmol/l, IC50 for aromatase = 0.00000089 mM
0.01
sulfamic acid 4-(3-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)propylsulfanyl)phenyl ester
Homo sapiens
-
inhibition of STS activity in JEG-3 cells tested with concentrations of 0.001-10000 nmol/l, IC50 larger than 0.01 mM, IC50 for aromatase = 0.00000051 mM
0.001
sulfamic acid 4-(5-((4-cyanophenyl)-[1,2,4]triazol-4-ylamino)pentylsulfanyl)phenyl ester
Homo sapiens
-
inhibition of STS activity in JEG-3 cells tested with concentrations of 0.001-10000 nmol/l, IC50 for aromatase = 0.00000073 mM
0.00059
sulfamic acid 5-[[(4-cyanophenyl)[1,2,4]triazol-4-ylamino]-methyl]-2-fluorophenyl ester
Homo sapiens
-
-
0.00000076 - 0.0000053
TX-1299
-
0.0000225
TX-1492
Homo sapiens
-
non-steroid Theramex compound, strong inhibitor, IC50: 22.5 nM in JEG-3 cells
-
0.00000006 - 0.0000119
TX-1506
-
additional information
1-[(4-cyanophenyl)(4-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole
0.000000035
3-sulfamoyloxy-N-3,3,3-trifluoropropyl-16,17-seco-estra-1,3,4(10)-triene-16,17-imide
Rattus norvegicus
-
in vitro JEG-3 cells: 0.001-10000 nmol/l inhibitor and incubation with estrone-3-sulfate, IC50 for human carbonic anhydrase II = 0.000003 mM
0.000000035
3-sulfamoyloxy-N-3,3,3-trifluoropropyl-16,17-seco-estra-1,3,4(10)-triene-16,17-imide
Homo sapiens
in vitro JEG-3 cells: 0.001-10000 nmol/l inhibitor and incubation with estrone-3-sulfate, IC50 for human carbonic anhydrase II = 0.000003 mM
0.00000043
6-oxo-8,9,10,11-tetrahydro-7H-cyclohepta-[c][1]benzopyran-3-O-sulfamate
Homo sapiens
-
IC50 0.43 nM in MCF-7 cells
0.0000051
6-oxo-8,9,10,11-tetrahydro-7H-cyclohepta-[c][1]benzopyran-3-O-sulfamate
Homo sapiens
-
6,6,7-COUMATE, IC50: 5.1 nM in JEG-3 cells
0.000008
6-oxo-8,9,10,11-tetrahydro-7H-cyclohepta-[c][1]benzopyran-3-O-sulfamate
Rattus norvegicus
-
667 COUMATE, placental IC50: 8 nM
0.00000008
estrone-3-sulfamate
Homo sapiens
-
IC50 0.08 nM in MCF-7 cells
0.0000032
estrone-3-sulfamate
Homo sapiens
-
best inhibitor, IC50: 3.2 nM in JEG-3 cells
0.00000018
STX213
Rattus norvegicus
-
in vitro JEG-3 cells: 0.001-10000 nmol/l inhibitor and incubation with estrone-3-sulfate, IC50 for human carbonic anhydrase II = 0.000005 mM
0.00000018
STX213
Homo sapiens
in vitro JEG-3 cells: 0.001-10000 nmol/l inhibitor and incubation with estrone-3-sulfate, IC50 for human carbonic anhydrase II = 0.000005 mM
0.0000015
STX64
Homo sapiens
enzyme activity in JEG-3 cells, IC50 for aromatase = 0.0003 mM
0.0000015
STX64
Homo sapiens
-
inhibition of STS activity in JEG-3 cells tested with concentrations of 0.001-10000 nmol/l, IC50 for aromatase = 0.0003 mM
0.000008
STX64
Homo sapiens
-
placental microsomes, pH not specified in the publication, temperature not specified in the publication
0.00000076
TX-1299
Homo sapiens
-
non-steroid Theramex compound, strong inhibitor, 0.76 nM in MCF-7 cells
-
0.0000053
TX-1299
Homo sapiens
-
non-steroid Theramex compound, strong inhibitor, IC50: 5.3 nM in JEG-3 cells
-
0.00000006
TX-1506
Homo sapiens
-
non-steroid Theramex compound, strong inhibitor, 0.06 nM in MCF-7 cells
-
0.0000119
TX-1506
Homo sapiens
-
non-steroid Theramex compound, strong inhibitor, IC50: 11.9 nM in JEG-3 cells
-
additional information
1-[(4-cyanophenyl)(4-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole
Homo sapiens
at 10 microM 21.5% inhibition of STS activity in JEG-3 cells, IC50 for aromatase = 0.000013 mM
additional information
1-[bis-(3-sulfamoyloxy-4-methoxyphenyl)methyl]-1H-[1,2,4]triazole
Homo sapiens
at 10 microM 10.9% inhibition of STS activity in JEG-3 cells, 40% inhibition of aromatase
additional information
1-[bis-(3-sulfamoyloxyphenyl)methyl]-1H-[1,2,4]triazole
Homo sapiens
at 10 microM 31.4% inhibition of STS activity in JEG-3 cells, IC50 for aromatase = 0.000099 mM
additional information
1-[bis-(4-sulfamoyloxy-3-methoxyphenyl)methyl]-1H-[1,2,4]triazole
Homo sapiens
at 10 microM 11.9% inhibition of STS activity in JEG-3 cells, 33% inhibition of aromatase
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.